Clinical Trial Update: Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110) [Phase 3]

View source ↗

Summary

Phase 3 BY217/M2-110 evaluated the effect of roflumilast on pulmonary function and respiratory symptoms in patients with chronic obstructive pulmonary disease; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Daliresp (roflumilast)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease, COPD | Phase 3 | Status: COMPLETED